Liang Cheng, Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, shared his recent article on X:
“I am delighted to share this NEWEST article from Expert Review of Anticancer Therapy!
Congratulations to Professor Francesco Massari, Linda Danielli, and the Team.”
Authors: Linda Danielli, et al.
Summary of the article:
- Prostate cancer progression is largely driven by androgen receptor (AR) signaling, making androgen receptor signaling inhibitors (ARSIs) a cornerstone of treatment for castration-resistant prostate cancer (CRPC). However, resistance mechanisms necessitate novel therapeutic approaches.
- Recent advancements focus on combination therapies, including ARSIs with PARP inhibitors (PROpel, MAGNITUDE, TALAPRO-2 trials), radioligand therapies (radium-223, lutetium-177), and novel agents targeting DNA repair and alternative signaling pathways.
- Future directions emphasize biomarker-driven treatment selection, optimized therapy sequencing, and innovative strategies to overcome resistance, aiming to enhance clinical outcomes and personalize care in CRPC management.
More posts featuring Liang Cheng.